Q-linea Q1 2022: Sales and commercial valuation progress - Redeye

Q-linea’s partner Thermo Fisher is launching ASTar in Europe. In Q1, the first ASTar is sold in the UK, and Q-linea points to “considerable interest” in ASTar. Q-linea also points to an indicative nine months sales cycle, intending to shorten this cycle. We expect a negative short term response to Q1, where considerable progress is balanced by a relatively long sales cycle. This is not any major surprise as ultra-fast AST testing is still an emerging technology. Our value proposition is a base of SEK 180 (Bull SEK 230 and Bear SEK 90).

Länk till analysen i sin helhet: https://www.redeye.se/research/840825/q-linea-q1-2022-sales-and-commercial-valuation-progress?utm_source=finwire&utm_medium=RSS